Pyramax® receives positive opinion from the EMA | MMV

Pyramax®, a fixed-dose combination of pyronaridine and artesunate, becomes the first antimalarial to be granted a positive scientific opinion from the European Medicines Agency EMA under Article 58. This once daily, 3-day treatment is indicated for acute, uncomplicated Plasmodium falciparum and blood-stage Plasmodium vivax malaria in adults and children over 20 kg.

via Pyramax® receives positive opinion from the EMA | MMV.

Advertisements


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s